143 related articles for article (PubMed ID: 32072403)
1. Investigation of promoter methylation of FSCN1 gene and FSCN1 protein expression in differentiated thyroid carcinomas.
Mahdiannasser M; Haghpanah V; Damavandi E; Kabuli M; Tavangar SM; Larijani B; Ghadami M
Mol Biol Rep; 2020 Mar; 47(3):2161-2169. PubMed ID: 32072403
[TBL] [Abstract][Full Text] [Related]
2. Promoter Methylation-Regulated miR-145-5p Inhibits Laryngeal Squamous Cell Carcinoma Progression by Targeting FSCN1.
Gao W; Zhang C; Li W; Li H; Sang J; Zhao Q; Bo Y; Luo H; Zheng X; Lu Y; Shi Y; Yang D; Zhang R; Li Z; Cui J; Zhang Y; Niu M; Li J; Wu Z; Guo H; Xiang C; Wang J; Hou J; Zhang L; Thorne RF; Cui Y; Wu Y; Wen S; Wang B
Mol Ther; 2019 Feb; 27(2):365-379. PubMed ID: 30341010
[TBL] [Abstract][Full Text] [Related]
3. Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling.
Zhao Z; Herman JG; Brock MV; Sheng J; Zhang M; Liu B; Guo M
PLoS One; 2014; 9(11):e112336. PubMed ID: 25375359
[TBL] [Abstract][Full Text] [Related]
4. Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.
Sassa M; Hayashi Y; Watanabe R; Kikumori T; Imai T; Kurebayashi J; Kiuchi T; Murata Y
Thyroid; 2011 May; 21(5):511-7. PubMed ID: 21449767
[TBL] [Abstract][Full Text] [Related]
5. Silencing of the maspin gene by promoter hypermethylation in thyroid cancer.
Boltze C; Schneider-Stock R; Quednow C; Hinze R; Mawrin C; Hribaschek A; Roessner A; Hoang-Vu C
Int J Mol Med; 2003 Oct; 12(4):479-84. PubMed ID: 12964023
[TBL] [Abstract][Full Text] [Related]
6. Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.
Beltrami CM; Dos Reis MB; Barros-Filho MC; Marchi FA; Kuasne H; Pinto CAL; Ambatipudi S; Herceg Z; Kowalski LP; Rogatto SR
Clin Epigenetics; 2017; 9():45. PubMed ID: 28469731
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional regulation of the potential tumor suppressor ABI3 gene in thyroid carcinomas: interplay between methylation and NKX2-1 availability.
Moraes L; Galrão AL; Rubió I; Cerutti JM
Oncotarget; 2016 May; 7(18):25960-70. PubMed ID: 27036019
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation signatures identify biologically distinct thyroid cancer subtypes.
Rodríguez-Rodero S; Fernández AF; Fernández-Morera JL; Castro-Santos P; Bayon GF; Ferrero C; Urdinguio RG; Gonzalez-Marquez R; Suarez C; Fernández-Vega I; Fresno Forcelledo MF; Martínez-Camblor P; Mancikova V; Castelblanco E; Perez M; Marrón PI; Mendiola M; Hardisson D; Santisteban P; Riesco-Eizaguirre G; Matías-Guiu X; Carnero A; Robledo M; Delgado-Álvarez E; Menéndez-Torre E; Fraga MF
J Clin Endocrinol Metab; 2013 Jul; 98(7):2811-21. PubMed ID: 23666970
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma.
Li JY; Han C; Zheng LL; Guo MZ
Chin Med J (Engl); 2012 Oct; 125(19):3526-31. PubMed ID: 23044318
[TBL] [Abstract][Full Text] [Related]
10. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
11. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
[TBL] [Abstract][Full Text] [Related]
12. FSCN1 is upregulated by SNAI2 and promotes epithelial to mesenchymal transition in head and neck squamous cell carcinoma.
Wang L; Jia Y; Jiang Z; Gao W; Wang B
Cell Biol Int; 2017 Aug; 41(8):833-841. PubMed ID: 28488774
[TBL] [Abstract][Full Text] [Related]
13. Papillary carcinoma of the thyroid: methylation is not involved in the regulation of MET expression.
Scarpino S; Di Napoli A; Rapazzotti-Onelli M; Pilozzi E; Ruco L
Br J Cancer; 2004 Aug; 91(4):703-6. PubMed ID: 15266330
[TBL] [Abstract][Full Text] [Related]
14. The tumor-promoting function of ECRG4 in papillary thyroid carcinoma and its related mechanism.
Chen J; Liu C; Yin L; Zhang W
Tumour Biol; 2015 Feb; 36(2):1081-9. PubMed ID: 25326809
[TBL] [Abstract][Full Text] [Related]
15. FSCN1 is an effective marker of poor prognosis and a potential therapeutic target in human tongue squamous cell carcinoma.
Chen Y; Tian T; Li ZY; Wang CY; Deng R; Deng WY; Yang AK; Chen YF; Li H
Cell Death Dis; 2019 May; 10(5):356. PubMed ID: 31043585
[TBL] [Abstract][Full Text] [Related]
16. The role of microRNA-133b and its target gene FSCN1 in gastric cancer.
Guo L; Bai H; Zou D; Hong T; Liu J; Huang J; He P; Zhou Q; He J
J Exp Clin Cancer Res; 2014 Nov; 33(1):99. PubMed ID: 25433493
[TBL] [Abstract][Full Text] [Related]
17. Silencing GPX3 Expression Promotes Tumor Metastasis in Human Thyroid Cancer.
Zhao H; Li J; Li X; Han C; Zhang Y; Zheng L; Guo M
Curr Protein Pept Sci; 2015; 16(4):316-21. PubMed ID: 25929866
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
[TBL] [Abstract][Full Text] [Related]
19. PTEN promoter methylation in sporadic thyroid carcinomas.
Alvarez-Nuñez F; Bussaglia E; Mauricio D; Ybarra J; Vilar M; Lerma E; de Leiva A; Matias-Guiu X;
Thyroid; 2006 Jan; 16(1):17-23. PubMed ID: 16487009
[TBL] [Abstract][Full Text] [Related]
20. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma.
Schagdarsurengin U; Gimm O; Dralle H; Hoang-Vu C; Dammann R
Thyroid; 2006 Jul; 16(7):633-42. PubMed ID: 16889486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
